Review of currently available large scale software for antibody analysis.
Today’s biologics R&D is slowed by fragmented tools and manual data wrangling; the paper proposes a unified, open-architecture platform that spans registration, tracking, analysis, and decisions from discovery through developability.
Key components are end-to-end registration of molecules/materials/assays; a harmonized data schema with normalized outputs; automated analytics with consistent QC; complete metadata capture and “data integrity by design.”
The platform should natively interface with AI, enable multimodal foundation models and continuous “lab-in-the-loop” learning, and support federated approaches to counter data scarcity while preserving privacy.
Dotmatics, Genedata, and Schrödinger each cover pieces (e.g., LiveDesign lacks end-to-end registration), and the authors stress regulatory-ready features.